📊 BCYC Key Takeaways
Is Bicycle Therapeutics PLC (BCYC) a Good Investment?
Bicycle Therapeutics is a pre-commercial pharmaceutical company with strong cash position ($628.1M) supporting runway, but demonstrates severe unprofitability with -$252.0M free cash flow burn and -301.7% net margin. While 105.8% revenue growth is encouraging, the company is consuming cash rapidly with operating losses of -$247.1M, raising questions about path to profitability and capital efficiency.
Bicycle Therapeutics shows strong top-line growth and an exceptionally strong balance sheet, with $628.11M in cash, very low leverage, and ample liquidity to fund operations. However, the business remains deeply unprofitable, with operating and free cash flow losses far exceeding revenue, which suggests current growth is not yet translating into durable operating quality. Fundamentally, this is a well-capitalized but high-burn biotech story where balance-sheet strength offsets weak profitability.
Why Buy Bicycle Therapeutics PLC Stock? BCYC Key Strengths
- Exceptional liquidity with $628.1M cash and 11.98x current ratio providing substantial runway
- Strong revenue growth of 105.8% YoY demonstrating commercial traction
- Minimal leverage with 0.05x debt-to-equity ratio and only $30.9M long-term debt
- 16 Form 4 insider filings in last 90 days suggest active management engagement
- Very strong liquidity, with current and quick ratios of 11.98x and $628.11M in cash
- Low financial leverage, with debt/equity of just 0.05x and modest long-term debt
- Revenue grew 105.8% YoY, indicating meaningful business or partnership momentum
BCYC Stock Risks: Bicycle Therapeutics PLC Investment Risks
- Massive cash burn of $252.0M FCF with -347.2% FCF margin indicating unsustainable trajectory
- Operating losses of -$247.1M far exceed revenue generation, showing negative unit economics
- Negative interest coverage of -300.9x means company cannot service debt from operations
- Revenue growth insufficient to offset operating losses; burn rate suggests 2-3 years of cash runway at current pace
- Typical biotech R&D model with high upfront costs, but sustained -$249.7M operating cash burn indicates commercialization challenges
- Operating margin of -340.4% and net margin of -301.7% show the business model is still far from self-sustaining
- Free cash flow of -$252.03M indicates heavy ongoing cash burn despite revenue growth
- Revenue quality may be uneven if growth is driven by milestone or collaboration payments rather than recurring commercial sales
Key Metrics to Watch
- Operating cash flow trend and path to cash flow breakeven
- Revenue growth sustainability and product pipeline advancement
- Operating expense ratio and efficiency improvements quarter-over-quarter
- Cash runway and burn rate deceleration trajectory
- Gross margin development once reported with higher revenue scale
- Quarterly operating cash burn relative to cash reserves
- Revenue mix and consistency, especially recurring product or collaboration revenue versus one-time items
Bicycle Therapeutics PLC (BCYC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 11.98x current ratio provides a solid financial cushion.
BCYC Profit Margin, ROE & Profitability Analysis
BCYC vs Healthcare Sector: How Bicycle Therapeutics PLC Compares
How Bicycle Therapeutics PLC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Bicycle Therapeutics PLC Stock Overvalued? BCYC Valuation Analysis 2026
Based on fundamental analysis, Bicycle Therapeutics PLC has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Bicycle Therapeutics PLC Balance Sheet: BCYC Debt, Cash & Liquidity
BCYC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Bicycle Therapeutics PLC's revenue has grown significantly by 426% over the 5-year period, indicating strong business expansion. The most recent EPS of $-5.08 indicates the company is currently unprofitable.
BCYC Revenue Growth, EPS Growth & YoY Performance
BCYC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.7M | -$26.6M | $-0.74 |
| Q2 2025 | $2.9M | -$26.6M | $-0.77 |
| Q1 2025 | $10.0M | -$26.6M | $-0.62 |
| Q3 2024 | $2.7M | -$26.6M | $-0.74 |
| Q2 2024 | $9.4M | -$26.6M | $-0.77 |
| Q1 2024 | $4.9M | -$26.6M | $-0.62 |
| Q3 2023 | $3.0M | -$26.8M | $-0.96 |
| Q2 2023 | $4.4M | -$26.8M | $-0.90 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Bicycle Therapeutics PLC Dividends, Buybacks & Capital Allocation
BCYC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Bicycle Therapeutics PLC (CIK: 0001761612)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 6, 2026 | 4 | xslF345X06/form4-04062026_060409.xml | View → |
| Apr 6, 2026 | 4 | xslF345X06/form4-04062026_060407.xml | View → |
| Apr 6, 2026 | 4 | xslF345X06/form4-04062026_060405.xml | View → |
| Apr 6, 2026 | 4 | xslF345X06/form4-04062026_060403.xml | View → |
| Apr 6, 2026 | 4 | xslF345X06/form4-04062026_060401.xml | View → |
❓ Frequently Asked Questions about BCYC
What is the AI rating for BCYC?
Bicycle Therapeutics PLC (BCYC) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BCYC's key strengths?
Claude: Exceptional liquidity with $628.1M cash and 11.98x current ratio providing substantial runway. Strong revenue growth of 105.8% YoY demonstrating commercial traction. ChatGPT: Very strong liquidity, with current and quick ratios of 11.98x and $628.11M in cash. Low financial leverage, with debt/equity of just 0.05x and modest long-term debt.
What are the risks of investing in BCYC?
Claude: Massive cash burn of $252.0M FCF with -347.2% FCF margin indicating unsustainable trajectory. Operating losses of -$247.1M far exceed revenue generation, showing negative unit economics. ChatGPT: Operating margin of -340.4% and net margin of -301.7% show the business model is still far from self-sustaining. Free cash flow of -$252.03M indicates heavy ongoing cash burn despite revenue growth.
What is BCYC's revenue and growth?
Bicycle Therapeutics PLC reported revenue of $72.6M.
Does BCYC pay dividends?
Bicycle Therapeutics PLC does not currently pay dividends.
Where can I find BCYC SEC filings?
Official SEC filings for Bicycle Therapeutics PLC (CIK: 0001761612) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BCYC's EPS?
Bicycle Therapeutics PLC has a diluted EPS of $-3.16.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BCYC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Bicycle Therapeutics PLC has a SELL rating with 82% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BCYC stock overvalued or undervalued?
Valuation metrics for BCYC: ROE of -35.9% (sector avg: 15%), net margin of -301.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BCYC stock in 2026?
Our dual AI analysis gives Bicycle Therapeutics PLC a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BCYC's free cash flow?
Bicycle Therapeutics PLC's operating cash flow is $-249.7M, with capital expenditures of $2.4M. FCF margin is -347.2%.
How does BCYC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -301.7% (avg: 12%), ROE -35.9% (avg: 15%), current ratio 11.98 (avg: 2).